Pluristem Therapeutics (PSTI) Says FDA Cleared its Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study
Tweet Send to a Friend
Pluristem Therapeutics Inc. (NASDAQ: PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
